Ocugen (OCGN) said Wednesday that it signed a licensing agreement with Roots Pharmaceutical and Al-Dhow International for exclusive Middle East and North Africa rights to its OCU400 gene therapy for retinitis pigmentosa.
Ocugen said it could receive up to $4 million in development milestones, $255 million in sales milestones and 22% royalties on net sales.
The company said it will manufacture commercial supplies. Phase 3 trial results are expected in Q1 2027, ahead of planned global regulatory submissions, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments